Considering Using Steroids? Understanding Your Risks

Member Access Required

Already a member? Sign In

Timeline

00:00

The introduction frames steroid use as a decision with both short term and long term consequences. It promises a scientific overview focused on what clinicians see in new users.

00:59

Hair loss is discussed as a head level side effect that can become permanent when predisposition exists. The segment encourages men to reconsider use if hair preservation is a priority.

01:24

Acne vulgaris is presented as multifactorial and sometimes resistant to simple hygiene advice. It warns that prior acne history can predict worse outbreaks during androgen exposure.

02:00

Edema and facial puffiness are described as dose dependent, especially with estrogenic stacking patterns. Hypertension is mentioned as a downstream concern when intravascular volume rises.

02:53

Cardiac risk is framed around hypertension, lipids, and clotting events interacting with genetics. Family history of heart attacks, bypass, or stents is treated as a major warning sign.

05:14

Lipid changes are described as a classic pattern where HDL drops and LDL can rise. The segment advises awareness because diet and exercise cannot always offset drug driven shifts.

06:09

Polycythemia and androgen induced erythrocytosis are described as thick blood mechanisms that raise risk. The segment links this to clot events like DVT and pulmonary embolism concerns.

06:28

Renal risk is highlighted, especially when kidney disease runs in families or hypertension exists. The segment cautions that short term steroid use can still stress kidney function.

06:42

Oral steroids are described as alpha alkylated drugs that elevate liver enzymes on laboratory testing. The segment notes uncertainty about what repeated enzyme elevations mean long term.

08:30

Sexual function and fertility are discussed as complicated, with hypersexuality during use and dysfunction after stopping. The segment urges avoidance if baseline sexual function is highly valued.

09:59

Central nervous system effects are discussed, including worsened depression, anxiety, or mania susceptibility. It warns that even mild cycles can destabilize vulnerable mental health patterns.

10:46

Musculoskeletal risks include tendon injury and ruptures with rapid strength gains. The segment lists common rupture sites and admits mechanisms are not fully understood clinically.

11:23

Additional polypharmacy is described, including growth hormone, peptides, and PCT medications in complex stacks. Clenbuterol, diuretics, thyroid preparations, and hCG are mentioned as common add ons.

12:46

Long term anabolic steroid induced hypogonadism is presented as a major consequence after crossing cumulative exposure lines. The segment describes persistent symptoms and possible lifelong testosterone dependence.

16:52

Long term cardiac outcomes include accelerated heart disease and possible steroid induced cardiomyopathy development. Arrhythmias, SVT, atrial fibrillation, and myocardial effects are discussed as rare but serious.

17:16

Long term kidney disease is described, including chronic kidney disease in heavy long term users. Focal segmental glomerulosclerosis is referenced as a severe pathology seen in some cases.

20:05

A mitigation section recommends baseline vital signs and comprehensive laboratory testing before any cycle decision. Suggested panels include CBC, metabolic testing, lipids, A1c, and hormone markers.

21:03

Cardiac imaging is suggested for selected individuals, including transthoracic echocardiography for ventricular size and function. Early diastolic dysfunction screening is mentioned as a helpful risk signal.

21:13

Coronary artery calcium scoring is presented as an additional tool for cardiovascular risk stratification. The segment stresses that age and family history should guide how aggressive screening becomes.

Video Summary

The transcript opens by warning that anabolic androgenic steroid use carries short term and long term risks. It proposes a head to toe framework so people can anticipate predictable problem areas quickly. Hair loss is described as a common early consequence when genetic predisposition already exists. Acne vulgaris is discussed as complicated, because mechanisms and individual triggers vary widely. The discussion notes that edema and facial puffiness can appear, especially with estrogenic combinations. Gynecomastia is presented as variable, driven by aromatization, genetics, and polypharmacy patterns. From the start, the message is that risk awareness should precede any first cycle decision. The tone stays educational while emphasizing that many regrets begin with casual experimentation.

Cardiovascular risk is framed as hypertension, lipid deterioration, and hypercoagulable clot scenarios. Family history is emphasized, because early heart attacks or stents signal inherited vulnerability. The transcript explains that steroids can lower HDL and raise LDL, compounding dietary issues. Polycythemia and androgen induced erythrocytosis are mentioned as thick blood mechanisms increasing risk. Renal effects are highlighted, particularly when baseline hypertension or kidney disease already exists. Oral alpha alkylated steroids are described as reliably elevating liver enzymes on laboratory testing. Prostate issues such as benign prostatic hyperplasia and prostatitis are raised for older men. Sexual function and fertility changes are portrayed as unpredictable, especially after stopping drugs.

Central nervous system effects are discussed, including worsened depression for vulnerable individuals. Withdrawal and long term anabolic steroid induced hypogonadism are framed as major life changing outcomes. The transcript notes that sex hormone binding globulin can remain elevated years after exposure. Cardiomyopathy and arrhythmias are described as possible long term consequences beyond simple plaque disease. Chronic kidney disease and focal segmental glomerulosclerosis are referenced in severe long term cases. The closing encourages a medical evaluation with vital signs and baseline labs before any use. Suggested testing includes CBC, metabolic panel, lipids, A1c, thyroid studies, and testosterone markers. Cardiac screening such as echocardiography and calcium scoring is presented as risk stratification.

Drug Callouts

Testosterone

Testosterone is the primary endogenous androgen and a prescribed therapy for confirmed hypogonadism. The transcript references testosterone based stacks as common contributors to edema and hypertension.

Nandrolone decanoate (Deca)

Nandrolone decanoate is a long acting anabolic steroid often called Deca in bodybuilding culture. The transcript mentions Deca as part of classic combinations linked to thick blood discussions.

Boldenone undecylenate (Equipoise)

Boldenone undecylenate is an injectable anabolic steroid commonly called Equipoise and derived from testosterone. The transcript references Equipoise when discussing thick blood and erythrocytosis mechanisms.

Methandrostenolone (Dianabol)

Methandrostenolone is an oral anabolic steroid commonly called Dianabol and known for rapid mass gain. The transcript lists Dianabol among estrogenic combinations that can worsen puffiness and blood pressure.

Clenbuterol

Clenbuterol is a beta two agonist sometimes misused for fat loss and stimulant effects. The transcript mentions clenbuterol as an additional polypharmacy item people add to complex regimens.

Human chorionic gonadotropin (hCG)

Human chorionic gonadotropin is a medication that can stimulate testicular testosterone production in some contexts. The transcript names hCG as a common during cycle or post cycle medication in steroid users.

Tamoxifen

Tamoxifen is a selective estrogen receptor modulator used in breast cancer and gynecomastia contexts. The transcript mentions tamoxifen as a post cycle drug users combine with other agents.

Clomiphene

Clomiphene is a selective estrogen receptor modulator used for certain infertility and hypogonadism evaluations. The transcript lists clomiphene as a common post cycle medication used after stopping steroids.

Aromatase inhibitors

Aromatase inhibitors are drugs that reduce conversion of testosterone into estradiol in tissues. The transcript mentions aromatase inhibitors when discussing gynecomastia risk and polypharmacy strategies.

Somatropin (growth hormone)

Somatropin is recombinant human growth hormone prescribed for specific deficiency conditions. The transcript references growth hormone as another drug people stack with steroids and peptides.

Condition Callouts

Acne vulgaris

Acne vulgaris is an inflammatory skin condition driven by follicular plugging and bacterial overgrowth. The transcript describes acne flares as a common early risk, especially with prior history.

Gynecomastia

Gynecomastia is benign enlargement of male breast gland tissue often influenced by hormonal imbalance. The transcript discusses variable gynecomastia risk related to aromatization and polypharmacy patterns.

Hypertension

Hypertension is persistently elevated blood pressure that increases cardiovascular and renal complications. The transcript links edema and estrogenic steroids to higher blood pressure and cardiac risk.

Polycythemia

Polycythemia is an abnormally high red blood cell concentration that increases blood viscosity. The transcript references androgen induced erythrocytosis as a mechanism that can raise clot risk.

Anabolic steroid induced hypogonadism

Anabolic steroid induced hypogonadism is prolonged suppression of the hypothalamic pituitary gonadal axis after exposure. The transcript frames this as a major long term consequence that can require lifelong testosterone.

Chronic kidney disease

Chronic kidney disease is long term reduction in kidney function that can progress toward failure. The transcript warns that steroid use can worsen kidney outcomes, especially with hypertension present.

Focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis is a kidney disease where scarring damages glomeruli and reduces filtration. The transcript cites focal segmental glomerulosclerosis as a severe pathology seen in some steroid users.

Benign prostatic hyperplasia

Benign prostatic hyperplasia is noncancerous prostate enlargement that can obstruct urinary flow. The transcript states that prostate enlargement and lower urinary symptoms can worsen with androgen exposure.

Prostatitis

Prostatitis is inflammation of the prostate that can cause pelvic pain and urinary symptoms. The transcript describes prostatitis and pelvic pain syndrome complaints appearing in men who use steroids.

Cardiomyopathy

Cardiomyopathy is disease of the heart muscle that can weaken pumping function or cause arrhythmias. The transcript references anabolic steroid induced cardiomyopathies and ventricular arrhythmia scenarios.

Key Takeaways

Short term risks include hair loss, acne, edema, and variable gynecomastia development.
Cardiovascular concerns include hypertension, HDL lowering, LDL changes, and clot risks.
Polycythemia and androgen induced erythrocytosis are described as thick blood mechanisms.
Long term consequences include hypogonadism, cardiomyopathy, and chronic kidney disease scenarios.
Baseline labs and targeted screening are recommended to mitigate avoidable steroid harms.